Clinical Trials

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

37 enrolled

Breast

HER2-low Breast Cancer

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07142200 2025-08-26

DECIDING

45 enrolled

Tumor-Agnostic

Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

74 enrolled

Breast

Breast Neoplasms

NCT06540729 2025-07-08

DAB

Phase 2 Active not recruiting

39 enrolled

Gynecologic

Ovarian Neoplasms

NCT05586061 2025-02-07

RCTS

55 enrolled

HER2-positive Gastric Cancer

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

110 enrolled

Stomach Neoplasms

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

58 enrolled

Thoracic

Lung Neoplasms

NCT06560528 2024-08-19

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

40 enrolled

Stomach Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Neoplasms

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

HER2-positive Gastric Cancer

NCT06385873 2024-05-13

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

32 enrolled

Stomach Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

63 enrolled

Pancreatic Neoplasms

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

108 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05578287 2023-12-07

DETECT

29 enrolled

Colorectal Neoplasms

NCT06074484 2023-10-10

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

36 enrolled

Muscle Invasive Bladder Carcinoma

NCT05957757 2023-08-31

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Non-Muscle Invasive Bladder Neoplasms

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

6 enrolled

Muscle Invasive Bladder Cancer

NCT05912205 2023-06-22

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

30 enrolled

Carcinoma, Transitional Cell

NCT05726175 2023-02-13

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Breast

Breast Neoplasms

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

30 enrolled

Stomach Neoplasms

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

29 enrolled

Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT05016973 2021-08-23

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer

25 enrolled